The company has also dosed first patient in the trial.
The trial is designed to investigate the safety and escalating doses of OMP-59R5 in patients who have received prior treatment with standard chemotherapeutics.
The Phase 1 trial also evaluates the pharmacokinetics, biomarkers and initial indications of efficacy.
In the previous studies OMP-59R5 has demonstrated decrease in the frequency of tumor-initiating cells across a variety of tumor types.
OncoMed Pharma president and CEO Paul Hastings said that the advancement of the second antibody into the clinic represents an important milestone for OncoMed, demonstrating productive drug discovery capabilities and steady execution on our objectives for the programs.